$34.9 M

ONTX Mkt cap, 16-Aug-2018

$1 M

Onconova Therapeutics Revenue Q2, 2018
Onconova Therapeutics Net income (Q2, 2018)-9.4 M
Onconova Therapeutics EBIT (Q2, 2018)-11.5 M
Onconova Therapeutics Cash, 30-Jun-201829.5 M

Onconova Therapeutics Income Statement

Annual

USDFY, 2016FY, 2017

Revenue

5.5 m787 k

R&D expense

20.1 m19.1 m

General and administrative expense

9.2 m7.4 m

Operating expense total

29.2 m26.5 m

EBIT

(23.7 m)(25.7 m)

EBIT margin, %

(427%)(3270%)

Pre tax profit

(19.7 m)(24.1 m)

Income tax expense

14 k13 k

Net Income

(19.7 m)(24.1 m)

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

125 k114 k114 k123 k1.6 m1.5 m2.2 m1.7 m210 k110 k564 k1 m

R&D expense

12.9 m11.9 m9.5 m6.5 m5.3 m5.8 m5.6 m4 m4.9 m4.6 m8.6 m

General and administrative expense

4 m3.1 m3 m2.6 m2.2 m3.2 m2.1 m2 m2.1 m1.9 m3.9 m

Operating expense total

16.9 m15 m12.5 m9.1 m7.5 m9 m7.6 m6 m7 m6.9 m6.5 m12.6 m

EBIT

(16.8 m)(14.9 m)(12.3 m)(9 m)(5.9 m)(7.5 m)(5.4 m)(4.3 m)(6.8 m)(6.8 m)(5.9 m)(11.5 m)

EBIT margin, %

(13411%)(13060%)(10832%)(7282%)(362%)(510%)(240%)(261%)(3234%)(6145%)(1046%)(1100%)

Pre tax profit

(14.9 m)

Net Income

(16.8 m)(14.9 m)(12.4 m)(9 m)(5.9 m)(7.2 m)(5.4 m)(1.6 m)(8.3 m)(7 m)(5.1 m)(9.4 m)

Onconova Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

60 m43.6 m19.8 m21.4 m4 m

Accounts Receivable

141.8 m59 k

Inventories

4.4 m3.2 m1.8 m

Current Assets

104.4 m46.9 m23.2 m23.1 m4.9 m

PP&E

626 k420 k248 k152 k64 k

Total Assets

105.2 m47.3 m23.4 m23.2 m5 m

Accounts Payable

3.7 m4 m3.4 m5.3 m6.2 m

Short-term debt

Current Liabilities

10.3 m10.3 m7.6 m10.2 m10 m

Long-term debt

Total Liabilities

18.1 m15.8 m

Additional Paid-in Capital

311.1 m317.1 m328.3 m342.5 m350.5 m

Retained Earnings

(230.9 m)(294.6 m)(318.6 m)(338.2 m)(362.3 m)

Total Equity

80.9 m23.6 m10.8 m5.1 m

Financial Leverage

1.3 x2 x2.2 x4.5 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

55.5 m42.3 m33.7 m25.4 m22.2 m16.8 m12.8 m25.8 m15.4 m7.6 m7.3 m29.5 m

Accounts Receivable

477 k72 k

Inventories

1 m

Current Assets

73.8 m61.6 m36.4 m27.4 m25.7 m19.4 m16 m27.9 m16.4 m8.7 m8.6 m30.2 m

PP&E

609 k512 k348 k300 k273 k224 k200 k176 k129 k48 k34 k

Total Assets

74.6 m62.3 m36.7 m27.7 m26 m19.6 m16.2 m28.1 m16.6 m8.8 m8.6 m30.2 m

Accounts Payable

5 m5.4 m3.9 m4.2 m3.2 m3.3 m2.8 m4.1 m5.4 m5.4 m7 m5.9 m

Current Liabilities

11.9 m13 m10.8 m9.9 m8.7 m7.6 m9.1 m9 m9.9 m9 m10.6 m10 m

Total Liabilities

14.9 m15.5 m14.3 m

Additional Paid-in Capital

314.6 m316.3 m318.5 m319.4 m324.9 m331.5 m332.4 m341.9 m343 m349.1 m359.5 m386 m

Retained Earnings

(266.3 m)(281.2 m)(306.9 m)(315.9 m)(321.7 m)(325.8 m)(331.2 m)(332.8 m)(346.6 m)(356.1 m)(367.4 m)(370.9 m)

Total Equity

48.9 m35.7 m12.6 m4.6 m4.2 m6.8 m2 m10 m15.9 m

Financial Leverage

1.5 x1.7 x2.9 x6.1 x6.2 x2.9 x7.9 x2.8 x1.9 x

Onconova Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(62.6 m)(63.8 m)(24 m)(19.7 m)(24.1 m)

Depreciation and Amortization

446 k434 k150 k96 k88 k

Accounts Receivable

(28 k)

Inventories

(2.7 m)1.2 m1.2 m

Accounts Payable

(1.8 m)317 k(606 k)1.9 m863 k

Cash From Operating Activities

(61.4 m)(57.6 m)(15.8 m)(23.8 m)

Cash From Investing Activities

(40.6 m)39.8 m39.8 m

Cash From Financing Activities

80.5 m1.5 m7.5 m17.4 m6.4 m

Income Taxes Paid

435 k435 k

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(16.8 m)(14.9 m)(12.4 m)(9 m)(5.9 m)(7.2 m)(5.4 m)(1.6 m)(8.3 m)(7 m)(5.1 m)(9.4 m)

Depreciation and Amortization

24 k16 k30 k

Accounts Receivable

(418 k)(13 k)

Inventories

1 m

Accounts Payable

5 m5.4 m3.9 m4.2 m3.2 m(125 k)2.8 m4.1 m5.4 m5.4 m848 k456 k

Cash From Operating Activities

(5.5 m)(10.1 m)

Cash From Financing Activities

1.6 m8.7 m35.7 m

Onconova Therapeutics Ratios

USDY, 2018

Financial Leverage

1.9 x
Report incorrect company information